Pevonedistat-3001 (FL)

Pevonedistat-3001 (FL)

 A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML)


Study treatments


Inclusion criteria


Exclusion criteria


Participating sites




Link